SmartHeart

What SmartHeart does

SmartHeart, founded in 2013 and operating as a US subsidiary of Israel-based SHL Telemedicine, commercializes the first fully integrated, portable 12-lead ECG device branded as SmartHeart (marketed in the US under smartheartpro.com and getsmartheart.com). The core offering consists of three tightly integrated components: a lightweight (~1 pound) battery-powered 12-lead ECG hardware unit that operates on two AAA lithium batteries and produces results in approximately 30 seconds without gels, adhesives, or shaving; the SmartHeart Pro mobile application on iOS and Android that pairs via Bluetooth, guides electrode placement, transmits ECG data, and orders cardiologist review; and the SmartHeart Portal, a HIPAA-compliant cloud-based clinical web portal for healthcare providers to review ECG results, access preliminary reads, and compare historical tracings. The system is FDA-cleared (21 CFR Part 11), uses HIPAA-compliant data handling, and is paired with a 24/7 cardiologist interpretation service (board-certified cardiologists returning full interpretations in ~30 minutes) and unlimited preliminary reads performed by SHL clinical staff. SmartHeart serves hospitals and health systems, physician practices, workplaces, retail and convenient-care clinics, in-home care providers, telemedicine and mobile health companies, post-acute facilities, wellness practices, and individual patients (the latter via physician prescription).

The business model is a hybrid hardware-plus-recurring-revenue model: device sales to enterprise buyers (quote-based, pricing not publicly disclosed), supplemental subscription or per-use fees for cardiology review services, and direct-to-consumer device purchases with prescription through the company website. US operations are run from a 1-10 employee office at 350 Motor Parkway, Suite 204, Hauppauge, NY, with customer care available 10am-6pm EDT. Distribution combines direct enterprise sales (demo requests), physician-prescribed home use, the consumer website, and mobile-app storefronts (Apple App Store listing is currently the Israel storefront, Google Play globally). Marketing spans the corporate website, social media (Facebook, Instagram, Twitter, LinkedIn), industry events (RosettaFest 2025), whitepaper/content marketing, and direct demo funnels. No revenue, funding rounds, customer logos (beyond individual physician testimonials), or M&A activity are disclosed; growth signals are limited to cumulative usage (1M+ ECGs delivered) and continued event participation rather than hiring or fundraising metrics.

Name

SmartHeart

Legal name

SmartHeart

Website

https://smartheartpro.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

SmartHeart is a US subsidiary of SHL Telemedicine that sells an FDA-cleared, fully integrated portable 12-lead ECG device paired with a 24/7 cardiologist interpretation service. It serves hospitals, physician practices, workplaces, post-acute facilities, telehealth companies, wellness practices, and individual patients (with prescription).

Ownership category

akta.pro rank

Product category

Portable Cardiac Diagnostic Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)

akta.pro secondary industries

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Cardiology Telemedicine Platforms (HLALAGAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), ECG/EKG & Heart Rhythm Monitors (Consumer) (CRACAQAC)

Keywords

• Portable ECG devices
• Cardiac diagnostic equipment
• Telemedicine cardiology
• Remote patient monitoring
• 12-lead ECG technology

Headquarters

HQ city

New City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SmartHeart ECG Device Sales: Sale of portable 12-lead ECG hardware device to healthcare providers, workplaces, and patients. The device is FDA-cleared and sold for professional, workplace, and personal use.
2. Telemedicine and Cardiology Review Services: Subscription or per-use fees for 24/7 preliminary reads by SHL clinical staff and full cardiologist interpretations returned within 30 minutes. Unlimited preliminary reviews included with the service.
3. SmartHeart Pro Mobile App: Mobile application for device pairing, ECG performance, and result viewing, available on Apple App Store and Google Play Store.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

SmartHeart designs, manufactures, and sells the first fully integrated, portable, 12-lead ECG device that delivers hospital-grade electrocardiograms in approximately 30 seconds without requiring professional training, gels, or adhesives. The offering is a connected ecosystem comprising the lightweight ECG hardware (powered by two AAA lithium batteries and weighing about one pound), a Bluetooth-paired iOS/Android mobile app for guided electrode placement and result viewing, and a cloud-based clinical portal for healthcare providers. The company also bundles 24/7 preliminary ECG reads via SHL's global telemedicine center and on-demand full interpretations from a network of U.S. board-certified cardiologists returned in roughly 30 minutes.

Product overview

SmartHeart is a unified portable ECG ecosystem consisting of the SmartHeart Pro hardware device (a lightweight, battery-powered 12-lead ECG machine), the SmartHeart Pro mobile app (iOS/Android) for device pairing and data transmission via Bluetooth, and the SmartHeart Portal (cloud-based clinical web portal) for ECG review and cardiologist ordering. The system is complemented by 24/7 ECG interpretation services including unlimited preliminary reads by SHL clinical staff and optional full interpretations by board-certified cardiologists within 30 minutes.

Differentiator

Problem solved

Functional benefit

Brands

• SmartHeart Pro: Mobile application for performing ECGs and accessing cardiologist reviews
• SmartHeart Portal
• SHL Telemedicine

Products and services

• SmartHeart Pro Device The first fully integrated, portable, 12-lead ECG device that delivers hospital-grade EKGs in approximately 30 seconds. Weighs approximately one pound, runs on two AAA lithium batteries (about 100 ECGs per set), and requires no professional training, shaving, gels, or adhesives. Sold to healthcare providers, workplaces, and individual patients (with physician prescription) for professional, workplace, and at-home use.
• SmartHeart Pro Mobile App iOS and Android mobile application that pairs with the SmartHeart Pro device via Bluetooth, guides users through in-app electrode placement to ensure accurate ECG capture, transmits ECG data, displays results, and enables optional ordering of cardiologist review. Available on the Apple App Store and Google Play Store.
• SmartHeart Portal Cloud-based, HIPAA-compliant clinical web portal for healthcare providers to review patient ECG results, access preliminary SHL clinical staff reads, order full cardiologist interpretations, compare historical ECGs side-by-side, and share ECG reports via email.
• 24/7 ECG Review Services Subscription- and per-use-based cardiology review service providing unlimited preliminary reads by SHL clinical staff plus on-demand full ECG interpretations from a network of licensed, credentialed, and board-certified cardiologists, with full interpretations returned to users within approximately 30 minutes.

Quantifiable outcome

• Patients monitored with a 12-lead ECG at home for one year following a heart attack demonstrated 2X lower mortality than patients who received no monitoring
• +1 more outcomes

Named customers4 records

Segments9 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AliveCor: AliveCor (KardiaMobile) is the leading consumer/clinical single-lead ECG device maker, paired with a smartphone app and optional cardiologist review subscription. Both companies sell portable connected ECG hardware with telehealth interpretation services, targeting overlapping physician, employer, and consumer segments.
• iRhythm Technologies: iRhythm makes the Zio long-term cardiac monitoring patch, a prescription diagnostic device used by physicians for continuous arrhythmia detection. Both companies deliver physician-prescribed connected cardiac monitoring with cloud-based clinician workflows, competing for the same cardiology and hospital budgets.

Broad incumbents

• Philips (Cardiac Monitoring): Philips is a global incumbent in hospital ECG and patient monitoring (PageWriter, IntelliVue, remote cardiac monitoring services). SmartHeart competes for the same hospital procurement dollars as Philips but differentiates on portability, ease of use, and bundled telemedicine review.
• GE Healthcare (MUSE / MAC ECG): GE Healthcare's MAC resting ECG systems and MUSE cardiology information system dominate hospital ECG workflows. SmartHeart offers a more portable, training-free alternative that can complement or substitute for GE's clinical ECG hardware in lower-acuity settings.
• Welch Allyn / Baxter (Mortara): Welch Allyn (now part of Baxter Hillrom) sells professional resting ECG and ambulatory monitoring devices used in physician offices. SmartHeart targets the same physician practice segment with a more portable, app-connected workflow.
• CardioNet / BioTelemetry (now Philips): BioTelemetry (CardioNet, now Philips) was the pioneer in mobile cardiac telemetry and remote arrhythmia monitoring services. SmartHeart overlaps with BioTelemetry's post-MI and at-risk patient monitoring use cases, particularly through bundled clinician interpretation.
• Preventice Solutions (Boston Scientific): Preventice (BodyGuardian, now Boston Scientific) provides remote cardiac monitoring with wearable patches and clinician-reviewed reports. SmartHeart's portable 12-lead device competes for similar outpatient cardiology and post-discharge monitoring indications.

Emerging players

• HeartBeam: HeartBeam is an early-stage company developing a credit-card-sized 3-lead ECG device with cloud-based synthesis software for cardiac diagnostics. Like SmartHeart, it targets portable, connected cardiac diagnostics with AI-augmented interpretation for both clinical and at-home use.
• Apple (Apple Watch ECG): Apple Watch's FDA-cleared single-lead ECG feature is embedded in tens of millions of consumer devices. While not a clinical 12-lead replacement, Apple Watch is a major indirect competitor in the consumer/at-home cardiac self-monitoring segment where SmartHeart also operates.

Others

• SHL Telemedicine: SHL Telemedicine is SmartHeart's parent company and the operator of the global telemedicine center providing unlimited preliminary ECG reads and cardiologist interpretations. As a strategic partner/shareholder and service provider, SHL is both an enabler and a related-party dependency for SmartHeart's bundled offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/smartheartusa
• Facebookfacebook.com/SmartHeartUSA
• LinkedInlinkedin.com/company/shl-usa
• Instagraminstagram.com/smartheartusa

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SmartHeart